This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Osimertinib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | ||
| - | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] tyrosine kinase inhibitor. | + | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] [[tyrosine kinase]] inhibitor. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:05, 10 October 2023
| |||||||||||
References
- ↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015
- ↑ Ayeni D, Politi K, Goldberg SB. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clin Cancer Res. 2015 Sep 1;21(17):3818-20. PMID:26169963 doi:10.1158/1078-0432.CCR-15-1211
- ↑ Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-e459. PMID:26370354 doi:10.1016/S1470-2045(15)00246-6
